{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Choice&page=2", "query": { "intervention": "Investigator's Choice", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 287, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Choice&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Choice&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T11:53:58.693Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Afatinib and Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2012-03", "completion_date": "2023-02-20", "has_results": true, "last_update_posted_date": "2023-11-01", "last_synced_at": "2026-10-06T11:53:58.693Z", "location_count": 9, "location_summary": "Los Angeles, California • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522768" }, { "nct_id": "NCT01154140", "title": "A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Squamous Lung Cancer" ], "interventions": [ { "name": "treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 343, "start_date": "2011-01-13", "completion_date": "2016-11-30", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-10-06T11:53:58.693Z", "location_count": 84, "location_summary": "Beverly Hills, California • Fontana, California • Loma Linda, California + 53 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fontana", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154140" }, { "nct_id": "NCT03085914", "title": "A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Investigator's choice of platinum agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-05-02", "completion_date": "2020-07-13", "has_results": true, "last_update_posted_date": "2022-09-23", "last_synced_at": "2026-10-06T11:53:58.693Z", "location_count": 16, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03085914" }, { "nct_id": "NCT03664024", "title": "Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2018-10-30", "completion_date": "2021-11-05", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-10-06T11:53:58.693Z", "location_count": 3, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03664024" }, { "nct_id": "NCT02264990", "title": "Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-squamous Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 595, "start_date": "2014-09-30", "completion_date": "2020-02-21", "has_results": true, "last_update_posted_date": "2021-02-26", "last_synced_at": "2026-10-06T11:53:58.693Z", "location_count": 25, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02264990" }, { "nct_id": "NCT03700320", "title": "Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Episodic Migraine" ], "interventions": [ { "name": "Standard of Care (SOC) Migraine Preventive Medication", "type": "DRUG" }, { "name": "Atogepant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 744, "start_date": "2018-10-08", "completion_date": "2020-05-21", "has_results": true, "last_update_posted_date": "2021-06-15", "last_synced_at": "2026-10-06T11:53:58.693Z", "location_count": 112, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03700320" }, { "nct_id": "NCT02756962", "title": "Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Allogeneic stem cell transplant", "type": "PROCEDURE" }, { "name": "Bone marrow aspiration", "type": "PROCEDURE" }, { "name": "Punch skin biopsy", "type": "PROCEDURE" }, { "name": "ClinSeq", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 107, "start_date": "2016-07-06", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-10-06T11:53:58.693Z", "location_count": 3, "location_summary": "Gainesville, Florida • St Louis, Missouri • Rochester, New York", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02756962" }, { "nct_id": "NCT05901285", "title": "Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab" ], "interventions": [ { "name": "VAX014", "type": "DRUG" }, { "name": "Nivolumab or pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Vaxiion Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2023-11-02", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-06T11:53:58.693Z", "location_count": 8, "location_summary": "Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05901285" }, { "nct_id": "NCT01655693", "title": "Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Doxorubicin 20 mg/m2", "type": "DRUG" }, { "name": "Doxorubicin 30 mg/m2", "type": "DRUG" }, { "name": "Best Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Valerio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 397, "start_date": "2012-06", "completion_date": "2019-05", "has_results": true, "last_update_posted_date": "2021-06-02", "last_synced_at": "2026-10-06T11:53:58.693Z", "location_count": 3, "location_summary": "Canton, Ohio • Hershey, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01655693" }, { "nct_id": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Vistusertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cediranib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 528, "start_date": "2017-12-18", "completion_date": "2026-09-11", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-06T11:53:58.693Z", "location_count": 17, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334617" } ] }